🇺🇸 FDA
Patent

US 7118738

Recombinant pox virus for immunization against MUC1 tumor-associated antigen

granted A61KA61K39/00

Quick answer

US patent 7118738 (Recombinant pox virus for immunization against MUC1 tumor-associated antigen) held by The United States of America, as represented by the Department of Health and Human Services expires Mon Oct 05 2026 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Department of Health and Human Services
Grant date
Tue Oct 10 2006 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 05 2026 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
37
CPC classes
A61K, A61K39/00